These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38281456)

  • 1. Financing COVID-19-related health care costs in the Dutch competitive health system during 2020 and 2021: Overall experiences and policy recommendations for improving health system resilience.
    Schut FT; Franken FME; van der Geest SA; Varkevisser M
    Health Policy; 2024 Mar; 141():104969. PubMed ID: 38281456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Netherlands: health system review.
    Schäfer W; Kroneman M; Boerma W; van den Berg M; Westert G; Devillé W; van Ginneken E
    Health Syst Transit; 2010; 12(1):v-xxvii, 1-228. PubMed ID: 21132996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managed competition in the Netherlands: Do insurers have incentives to steer on quality?
    Stolper KCF; Boonen LHHM; Schut FT; Varkevisser M
    Health Policy; 2019 Mar; 123(3):293-299. PubMed ID: 30268584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stuck in the middle?: A perspective on ongoing pro-competitive reforms in Dutch mental health care.
    Westra D; Wilbers G; Angeli F
    Health Policy; 2016 Apr; 120(4):345-9. PubMed ID: 26994866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Managed competition" for Ireland? The single versus multiple payer debate.
    Mikkers M; Ryan P
    BMC Health Serv Res; 2014 Sep; 14():442. PubMed ID: 25261074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addressing health care market reform through an insurance exchange: essential policy components, the public plan option, and other issues to consider.
    Fronstin P; Ross MN
    EBRI Issue Brief; 2009 Jun; (330):1-22. PubMed ID: 19545086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do health insurers use target marketing as a tool for risk selection? Evidence from the Netherlands.
    Stolper KCF; Boonen LHHM; Schut FT; Varkevisser M
    Health Policy; 2022 Feb; 126(2):122-128. PubMed ID: 35000802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competition policy for health care provision in the Netherlands.
    Schut FT; Varkevisser M
    Health Policy; 2017 Feb; 121(2):126-133. PubMed ID: 27923494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring Healthcare Providers' Performances Within Managed Competition Using Multidimensional Quality and Cost Indicators.
    Portrait FR; van der Galiën O; Van den Berg B
    Health Econ; 2016 Apr; 25(4):408-23. PubMed ID: 25702821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Citizen engagement in healthcare procurement decision-making by healthcare insurers: recent experiences in the Netherlands.
    Brito Fernandes Ó; Bos V; Klazinga N; Kringos D
    Health Res Policy Syst; 2022 Dec; 20(1):137. PubMed ID: 36550520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a business case for quality in The Netherlands? A critical analysis of the recent reforms of the health care system.
    Custers T; Arah OA; Klazinga NS
    Health Policy; 2007 Jul; 82(2):226-39. PubMed ID: 17070956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Netherlands: Health System Review.
    Kroneman M; Boerma W; van den Berg M; Groenewegen P; de Jong J; van Ginneken E
    Health Syst Transit; 2016 Mar; 18(2):1-240. PubMed ID: 27467715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global Health System Resilience during Encounters with Stressors - Lessons Learnt from Cancer Services during the COVID-19 Pandemic.
    Yeoh K; Wu Y; Chakraborty S; Elhusseiny G; Gondhowiardjo S; Joseph N; Lee AWM; Loong HH; Msadabwe-Chikuni SC; Tan BF; Ospina AV; Roques T; Shum HM; Yeoh EK
    Clin Oncol (R Coll Radiol); 2023 Apr; 35(4):e289-e300. PubMed ID: 36764875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How resilient is health financing policy in Europe to economic shocks? Evidence from the first year of the COVID-19 pandemic and the 2008 global financial crisis.
    Thomson S; García-Ramírez JA; Akkazieva B; Habicht T; Cylus J; Evetovits T
    Health Policy; 2022 Jan; 126(1):7-15. PubMed ID: 34857406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of purchaser competition in the Dutch health system: is the glass half full or half empty?
    Schut FT; van de Ven WP
    Health Econ Policy Law; 2011 Jan; 6(1):109-23. PubMed ID: 21269527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prices and market power in mental health care: Evidence from a major policy change in the Netherlands.
    Brouns C; Douven R; Kemp R
    Health Econ; 2021 Apr; 30(4):803-819. PubMed ID: 33502788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the reform of the Dutch healthcare into managed competition: Results of a Delphi study among experts.
    de Vries H; Vahl J; Muris J; Evers S; van der Horst H; Cheung KL
    Health Policy; 2021 Jan; 125(1):27-33. PubMed ID: 33189409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managed competition in the Netherlands-a qualitative study.
    Heinemann S; Leiber S; Gress S
    Health Policy; 2013 Feb; 109(2):113-21. PubMed ID: 23031431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferred providers and the credible commitment problem in health insurance: first experiences with the implementation of managed competition in the Dutch health care system.
    Boonen LH; Schut FT
    Health Econ Policy Law; 2011 Apr; 6(2):219-35. PubMed ID: 21122187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Managed competition in the health-care services - the Dutch experience].
    Ahrens D
    Gesundheitswesen; 2013 Jun; 75(6):386-92. PubMed ID: 23172597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.